Li Jian-ping, He Xue-lin, Li Qun
Department of TCM, The First Affiliated Hospital of Medical School, Zhejiang University, Hangzhou.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 May;26(5):415-8.
OBJECTIVE: To study the effects and the possible mechanism of Tangshenling (TSL) combined with telmisartan on early diabetic nephropathy (DN). Methods Eighty-one patients with early DN were randomly assigned into the control group (n=40) treated by telmisartan alone and the treated group (n=41) treated by TSL combined with telmisartan, and the conventional western therapy was given to all patients in both groups. Changes before and after treatment in symptoms and levels of urine albumin excretion rate (UAER), urine transforming growth factor beta1 (TGF-beta1), retinol binding protein (RBP) and beta2-microglobulin (beta2-MG), fasting blood glucose (FBG), serum creatinine (SCr), blood lipids, plasma atrial natriuretic peptide (ANP), serum collagen type IV (Col-IV) and TGF-beta1 were observed. RESULTS: Before treatment, no significant difference was shown in all these indexes between the treated group and the control group. After 8 weeks of treatment, the effective rates in symptoms improvement were higher in the treated group than those in the control group (P < 0.05 or P < 0.01); UAER, urine RBP, beta2-MG and TGF-beta1, serum TC, TG, Col-IV and TGF-beta1, and blood pressure were significantly lowered in both groups after treatment (P < 0.05 or P < 0.01); and the treated group showed a better effect than the control group in improving all the above-mentioned indexes except the blood pressure (P < 0.05); but there was no significant difference in the changes of FBG, SCr and blood pressure between the 2 groups (P > 0.05); after treatment, plasma ANP significantly lowered in the treated group (P < 0.01), while there was no significant change of that in the control group (P > 0.05). Conclusion Combination of TSL and telmisartan has a better effect than telmisartan on DN in early stage. Its mechanism might be related to the decrease of ANP and TGF-beta1 and improvement of lipids metabolism and renal tubular interstitial pathological changes.
目的:研究糖肾灵(TSL)联合替米沙坦对早期糖尿病肾病(DN)的影响及其可能机制。方法 将81例早期DN患者随机分为对照组(n = 40),单纯接受替米沙坦治疗;治疗组(n = 41),接受TSL联合替米沙坦治疗,两组患者均给予常规西医治疗。观察两组患者治疗前后症状、尿白蛋白排泄率(UAER)、尿转化生长因子β1(TGF-β1)、视黄醇结合蛋白(RBP)、β2-微球蛋白(β2-MG)、空腹血糖(FBG)、血清肌酐(SCr)、血脂、血浆心钠素(ANP)、血清Ⅳ型胶原(Col-Ⅳ)及TGF-β1水平的变化。 结果:治疗前,治疗组与对照组各项指标比较,差异均无统计学意义。治疗8周后,治疗组症状改善有效率高于对照组(P < 0.05或P < 0.01);两组治疗后UAER、尿RBP、β2-MG、TGF-β1、血清总胆固醇(TC)、甘油三酯(TG)、Col-Ⅳ及TGF-β1水平和血压均显著降低(P < 0.05或P < 0.01);除血压外,治疗组在改善上述各项指标方面均优于对照组(P < 0.05);但两组FBG、SCr及血压变化差异无统计学意义(P > 0.05);治疗后,治疗组血浆ANP显著降低(P < 0.01),而对照组无明显变化(P > 0.05)。结论 TSL联合替米沙坦治疗早期DN的效果优于单用替米沙坦,其机制可能与降低ANP、TGF-β1水平,改善脂质代谢及肾小管间质病理改变有关。
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006-5
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015-2
Zhong Xi Yi Jie He Xue Bao. 2006-1
J Renin Angiotensin Aldosterone Syst. 2011-3-18
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012-1
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004-12
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005-11
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006-9
J Renin Angiotensin Aldosterone Syst. 2014-12
Chin Med. 2016-2-24
Evid Based Complement Alternat Med. 2013-8-26